Marathon Pharmaceuticals’ pricing of Emflaza for Duchenne muscular dystrophy causes controversy

It’s not easy finding your way “from a garage to a palace...”

Sitting Down With Dominic Carolan, CEO of NIBRT.

Pharma needs new business model designs and analytics to help measure value.

Men continue to dominate upper management positions, but could flexible working change this?

What separates a good model from a bad model in bioprocess development?

What was hot in 2016? And what should pharma's priorities lie in 2017?

We investigate the advantages and limitations of microcalorimetry in biopharma.

Are current guidelines around packaging and product degradation up to scratch?

How inspiration from the airline industry could help improve the biosimilars industry.